1
|
Ranganathan S, Benjamin DJ, Haslam A, Prasad V. Social media engagement of supportive care publications in oncology. J Cancer Policy 2024; 41:100491. [PMID: 38852671 DOI: 10.1016/j.jcpo.2024.100491] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2024] [Accepted: 06/06/2024] [Indexed: 06/11/2024]
Abstract
IMPORTANCE There is an increasing number of cancer 'survivors' and increasing research into supportive care. However, it is unknown how patterns of attention and citation differ between supportive and non-supportive cancer care research. We sought to estimate the engagement of high-impact studies of supportive compared to non-supportive cancer care papers. METHODS In a cross-sectional review of top oncology journals (2016-2023), we reviewed studies examining supportive care strategies and a frequency-matched random sampling of studies on non-supportive interventions. We compared data on social engagement metrics, as represented by Altmetric scores and citations and funding status, by supportive care or non-supportive care articles. RESULTS We found overall Altmetric scores were no different between articles that did not test supportive care and those that did, with a numerically higher score for supportive care articles (86.0 vs 102; p=0.416). Other bibliometric statistics (such as the number of blogs, number of X users, and the number of X posts) obtained from Altmetric did not differ significantly between the two groups. Non-supportive cancer care papers had a significantly higher number of citations than supportive cancer care papers (45.6 in supportive care vs 141 in non-supportive care papers; p<0.001). A greater proportion of non-supportive cancer care papers were also supported by pharmaceutical companies compared to supportive cancer care papers (54.2 % vs 15.3 %; p<0.001). CONCLUSION Though social media engagement is similar between supportive and non-supportive cancer care papers in high-impact journals, there is a significant difference in support from pharmaceutical companies and the number of citations.
Collapse
Affiliation(s)
| | | | - Alyson Haslam
- Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA
| | - Vinay Prasad
- Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA.
| |
Collapse
|
2
|
Benjamin DJ, Rezazadeh Kalebasty A, Prasad V. The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma? Eur Urol Oncol 2024; 7:313-315. [PMID: 38485615 DOI: 10.1016/j.euo.2024.02.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2024] [Accepted: 02/29/2024] [Indexed: 05/19/2024]
Abstract
Recent findings reported for the phase 3 EV-302 trial indicate a survival benefit from enfortumab vedotin plus pembrolizumab versus chemotherapy in metastatic urothelial carcinoma. We discuss several key points regarding post-protocol therapies, extending the duration of therapy, toxicity, and costs, all of which may have a bearing on how physicians and patients balance the benefit against the potential harms associated with this regimen.
Collapse
Affiliation(s)
| | - Arash Rezazadeh Kalebasty
- Division of Hematology and Oncology, Department of Medicine, University of California-Irvine, Orange, CA, USA
| | - Vinay Prasad
- Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, CA, USA
| |
Collapse
|
3
|
Paravathaneni M, Safa H, Joshi V, Tamil MK, Adashek JJ, Ionescu F, Shah S, Chadha JS, Gilbert S, Manley B, Semaan A, Jim HS, Kalos D, Kim Y, Spiess PE, Chahoud J. 15 years of patient-reported outcomes in clinical trials leading to GU cancer drug approvals: a systematic review on the quality of data reporting and analysis. EClinicalMedicine 2024; 68:102413. [PMID: 38273886 PMCID: PMC10809115 DOI: 10.1016/j.eclinm.2023.102413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/10/2023] [Revised: 12/18/2023] [Accepted: 12/20/2023] [Indexed: 01/27/2024] Open
Abstract
Background Standardized, high-quality PRO data reporting is crucial for patient centered care in the field of oncology, especially in clinical trials that establish standard of care. This study evaluated PRO endpoint design, conduct and reporting methods in FDA approved drugs for GU malignancies. Methods A systematic review of the FDA archives identified GU cancer drug approvals from Feb 2007 to July 2022. ClinicalTrials.gov and PubMed were used to retrieve relevant data. PRO data was screened, and analytic tools, interpretation methods in the published papers and study protocols were reviewed. Compliance with PRO reporting standards were assessed using PRO Endpoint Analysis Score (PROEAS), a 24-point scoring scale from Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data Consortium (SISAQOL). Findings We assessed 40 trial protocols with 27,011 participants, resulting in 14 renal cell cancer (RCC), 16 prostate cancer (PC), and 10 urothelial cancer (UC) approvals. PRO data was published for 27 trials, with 23 PRO publications (85%) focusing solely on PRO data, while 4 (15%) included PRO data in the original paper. Median time between primary clinical and secondary paper with PRO data was 10.5 months (range: 9-25 months). PROs were not planned as primary endpoints for any study but 14 (52%) reported them as secondary, 10 (37%) as exploratory outcomes, and 3 (11%) lacked any clarity on PRO data as endpoint. Mean PROEAS score of all GU cancers was 11.10 (range: 6-15), RCC (11.86, range: 6-15), UC (11.50, range: 9-14), and PC (10.56, range: 6-15). None met all the SISAQOL recommendations. Interpretation Low overall PROEAS score and delays in PRO data publication in GU cancer drug trials conducted in the past decade emphasize the need for improvement in quality of design and conduct of PRO endpoint in future trials and accelerated publication of PRO endpoints, using standardized analysis, and prespecified hypothesis driven endpoint. These improvements are essential for facilitating interpretation and application of PRO study findings to define patient care. Funding None.
Collapse
Affiliation(s)
- Mahati Paravathaneni
- Department of Hematology and Oncology, H. Lee Moffitt Cancer Center, and Research Institute, Tampa, FL, 33612, USA
| | - Houssein Safa
- Department of Internal Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, 10467, USA
| | - Vidhu Joshi
- Participant Research, Villanova University Charles Widger School of Law, Villanova, PA, 19085, USA
| | - Monica K. Tamil
- Department of Hematology and Oncology, Baylor College of Medicine, Houston, TX, 77030, USA
| | - Jacob J. Adashek
- Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, 21231, USA
| | - Filip Ionescu
- Department of Hematology and Oncology, H. Lee Moffitt Cancer Center, and Research Institute, Tampa, FL, 33612, USA
| | - Savan Shah
- Department of Hematology and Oncology, H. Lee Moffitt Cancer Center, and Research Institute, Tampa, FL, 33612, USA
| | - Juskaran S. Chadha
- Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, and Research Institute, Tampa, FL, 33612, USA
| | - Scott Gilbert
- Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, and Research Institute, Tampa, FL, 33612, USA
| | - Brandon Manley
- Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, and Research Institute, Tampa, FL, 33612, USA
| | - Adele Semaan
- Participant Research, Interventions, and Measurements Core, H. Lee Moffitt Cancer Center, and Research Institute, Tampa, FL, 33612, USA
| | - Heather S.L. Jim
- Department of Health Outcomes and Behavior, H. Lee Moffitt Cancer Center, and Research Institute, Tampa, FL, 33612, USA
| | - Denise Kalos
- Department of Biostatistics, H. Lee Moffitt Cancer Center, and Research Institute, Tampa, FL, 33612, USA
| | - Youngchul Kim
- Department of Biostatistics, H. Lee Moffitt Cancer Center, and Research Institute, Tampa, FL, 33612, USA
| | - Philippe E. Spiess
- Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, and Research Institute, Tampa, FL, 33612, USA
| | - Jad Chahoud
- Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, and Research Institute, Tampa, FL, 33612, USA
| |
Collapse
|